Additional file 1 of Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

Gargiulo, Piera; Arenare, Laura; Gridelli, Cesare; Morabito, Alessandro; Ciardiello, Fortunato; Gebbia, Vittorio; Maione, Paolo; Spagnuolo, Alessia; Palumbo, Giuliano; Esposito, Giovanna; Della Corte, Carminia Maria; Morgillo, Floriana; Mancuso, Gianfranco; Di Liello, Raimondo; Gravina, Adriano; Schettino, Clorinda; Di Maio, Massimo; Gallo, Ciro; Perrone, Francesco; Piccirillo, Maria Carmela

doi:10.6084/m9.figshare.14594177.v1

12885_2021_8323_MOESM1_ESM.docx (51.2 kB)

Additional file 1 of Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

journal contribution

posted on 2021-05-14, 03:25 authored by Piera Gargiulo, Laura Arenare, Cesare Gridelli, Alessandro Morabito, Fortunato Ciardiello, Vittorio Gebbia, Paolo Maione, Alessia Spagnuolo, Giuliano Palumbo, Giovanna Esposito, Carminia Maria Della Corte, Floriana Morgillo, Gianfranco Mancuso, Raimondo Di Liello, Adriano Gravina, Clorinda Schettino, Massimo Di Maio, Ciro Gallo, Francesco Perrone, Maria Carmela Piccirillo

Additional file 1: Table S1. Main characteristics of the 6 randomized trials included in the pooled analysis. Table S2. Distribution of patients according to trial and treatment in the whole population and in landmark and out-of-landmark populations. Table S3. Patient characteristics in the whole eligible population (N = 1529) according to neutropenia. Table S4. Patient characteristics in the landmark population (N = 572) according to neutropenia. Table S5. Patient characteristics in the out-of-landmark population (N = 957) according to neutropenia. Table S6. Worst grade of neutropenia by treatment and trial in the landmark group. Figure S1. Distribution of worst grade of neutropenia over cycles in the landmark population.